TY - JOUR T1 - Financing Vaccines for Global Health Security JF - medRxiv DO - 10.1101/2020.03.20.20039966 SP - 2020.03.20.20039966 AU - Jonathan T. Vu AU - Benjamin K. Kaplan AU - Shomesh Chaudhuri AU - Monique K. Mansoura AU - Andrew W. Lo Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/23/2020.03.20.20039966.abstract N2 - Recent outbreaks of infectious pathogens such as Zika, Ebola, and COVID-19 have underscored the need for the dependable availability of vaccines against emerging infectious diseases (EIDs). The cost and risk of R&D programs and uniquely unpredictable demand for EID vaccines have discouraged vaccine developers, and government and nonprofit agencies have been unable to provide timely or sufficient incentives for their development and sustained supply. We analyze the economic returns of a portfolio of EID vaccine assets, and find that under realistic financing assumptions, the expected returns are significantly negative, implying that the private sector is unlikely to address this need without public-sector intervention. We have sized the financing deficit for this portfolio and propose several potential solutions, including price increases, enhanced public-private partnerships, and subscription models through which individuals would pay annual fees to obtain access to a portfolio of vaccines in the event of an outbreak.Competing Interest StatementShomesh Chaudhuri and Andrew Lo are principals at a consulting firm with clients in the biopharma industry. Lo also has personal investments in the biopharma industry, is on the board of Roivant Sciences, and is a co-founder and advisor to BridgeBio Pharma. Monique Mansoura is Executive Director Global Health Security and Biotechnology at Mitre Health, and collaborates with biopharma companies on issues related to the subject of this research.Funding StatementNo funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of this manuscript. No direct funding was received for this study. The authors were personally salaried by their institutions during the period of writing (though no specific salary was set aside or given for the writing of this manuscript).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and software used in this manuscript is publicly available. ER -